Literature DB >> 20938367

A simple and cost-effective method to transfect small interfering RNAs into pancreatic cancer cell lines using polyethylenimine.

Matthias Wirth1, Petra Fritsche, Natasa Stojanovic, Martina Brandl, Stephanie Jaeckel, Roland M Schmid, Dieter Saur, Günter Schneider.   

Abstract

OBJECTIVES: RNA interference, an indispensable tool in functional genomics, can be induced by small interfering RNAs (siRNAs). Because of the transient nature of siRNA-mediated RNA interference, the continuous use of transfection reagents is mandatory. Because transfection reagents are expensive, cost-effective alternatives must be considered. In this study, we describe a polyethylenimine-based siRNA transfection protocol for pancreatic cancer cell lines.
METHODS: For determination of polyethylenimine-based transfection efficiency, a FAM-labeled siRNA was transfected into several pancreatic cancer cell lines and subsequently analyzed by flow cytometry. The effective knockdown of 2 siRNAs was determined on the protein level by Western blot. Toxicity of the transfection reagent was analyzed by viability assays.
RESULTS: Polyethylenimine can be used without overt cellular morphological changes, and toxicity is negligible in human and murine pancreatic cancer cell lines. Transfection efficiencies ranged between 83% and 98% in the cell lines used. The knockdown at the protein level was comparable to commercially available transfection reagents. Polyethylenimine and siRNA concentrations, incubation time, and cell density are determinates of the transfection efficiency.
CONCLUSIONS: Polyethylenimine is a suitable and cost-effective alternative for transfecting siRNAs into pancreatic cancer cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20938367     DOI: 10.1097/MPA.0b013e3181f7e41c

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.

Authors:  Laura Conradt; Klaus Godl; Christoph Schaab; Andreas Tebbe; Stefan Eser; Sandra Diersch; Christoph W Michalski; Jörg Kleeff; Angelika Schnieke; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Neoplasia       Date:  2011-11       Impact factor: 5.715

2.  HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer.

Authors:  N Stojanovic; Z Hassan; M Wirth; P Wenzel; M Beyer; C Schäfer; P Brand; A Kroemer; R H Stauber; R M Schmid; A Arlt; A Sellmer; S Mahboobi; R Rad; M Reichert; D Saur; O H Krämer; G Schneider
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

3.  Targeting cancer cell-specific RNA interference by siRNA delivery using a complex carrier of affibody-displaying bio-nanocapsules and liposomes.

Authors:  Yuya Nishimura; Hiroaki Mieda; Jun Ishii; Chiaki Ogino; Toshinobu Fujiwara; Akihiko Kondo
Journal:  J Nanobiotechnology       Date:  2013-06-24       Impact factor: 10.435

4.  MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib.

Authors:  Matthias Wirth; Natasa Stojanovic; Jan Christian; Mariel C Paul; Roland H Stauber; Roland M Schmid; Georg Häcker; Oliver H Krämer; Dieter Saur; Günter Schneider
Journal:  Nucleic Acids Res       Date:  2014-08-21       Impact factor: 16.971

5.  A linear polyethylenimine mediated siRNA-based therapy targeting human epidermal growth factor receptor in SPC-A1 xenograft mice.

Authors:  Pinghai Zhang; Nuo Xu; Lei Zhou; Xin Xu; Yuehong Wang; Ka Li; Zhaochong Zeng; Xiangdong Wang; Xin Zhang; Chunxue Bai
Journal:  Transl Respir Med       Date:  2013-02-22

6.  Efemp1 and p27(Kip1) modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models.

Authors:  Sandra Diersch; Patrick Wenzel; Melanie Szameitat; Philipp Eser; Mariel C Paul; Barbara Seidler; Stefan Eser; Marlena Messer; Maximilian Reichert; Philipp Pagel; Irene Esposito; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Oncotarget       Date:  2013-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.